HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

▼

Showing posts with label OLYSIO™(Simeprevir) containing regimens. Show all posts

Showing posts with label OLYSIO™(Simeprevir) containing regimens. Show all posts

Sunday, December 10, 2017

Medivir announces Janssen decision to terminate its simeprevir license effective June 2018

Medivir announces Janssen decision to terminate its simeprevir license effective June 2018 Sun, Dec 10, 2017 11:30 CET Stockholm, Sweden ...

Monday, April 24, 2017

Update on the Development of Simeprevir as Part of the Triple Combination With AL-335 and Odalasvir (JNJ-4178)

Update on the Development of Simeprevir as Part of the Triple Combination With AL-335 and Odalasvir (JNJ-4178) STOCKHOLM , April 24, 2017 ...

Monday, April 11, 2016

Simeprevir/New Data Will Be Presented at Easl's International Liver Congress 2016

Medivir: New Data for Simeprevir Will Be Presented at Easl's International Liver Congress 2016 April 11, 2016 09:46 AM Eastern Daylight...

View web version

Powered by Blogger.